The Top 5 Biosimilar Articles for the Week of August 2

Here are the top 5 biosimilar articles for the week of August 2, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of August 2, 2021.

Number 5: BioFactura said it initiated a phase 1 clinical trial for its ustekinumab biosimilar candidate (BFI-751), referencing Janssen Biotech’s blockbuster product Stelara.

Number 4: Pfizer reported strong sales for its biosimilars portfolio, but these were eclipsed by the massive success of the company's messenger RNA (mRNA) vaccine for COVID-19.

Number 3: The approval of Biocon Biologics and Viatris' insulin glargine product as an interchangeable biosimilar will be a test of whether such designations can make a difference in patient access, Jeff Baldetti, MBA, of Cardinal Health explained.

Number 2: Sarfaraz K. Niazi, PhD, discussed the regulatory approval of future mRNA vaccines, which will likely face fewer patent issues and are easy to replicate.

Number 1: The FDA approved Biocon Biologic's Semglee, an insulin glargine product, as the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin.

To read all of these articles and more, visit centerforbiosimilars.com.